Unpacking the Clinical Question: HGNS and Cardiovascular Health

The core of the investigation centered on a critical clinical question: In adults grappling with obstructive sleep apnea, does the implantation of a hypoglossal nerve stimulator correlate with a reduced occurrence of cardiovascular disease? This question is of paramount importance given the widespread prevalence of OSA and its well-documented association with a spectrum of serious cardiovascular complications, including atrial fibrillation, stroke, heart failure, coronary artery disease, myocardial infarction, and premature death.

The Bottom Line: A Nuanced Picture Emerges

The study’s bottom line presents a nuanced perspective. Analyzing a substantial cohort of 3,786 patients who received HGNS and comparing them with 3,395 carefully matched controls who met the criteria for HGNS candidacy but did not undergo the procedure, researchers observed a mixed bag of outcomes. Over a two-year period, HGNS was associated with a lower incidence of new-onset diabetes and hypertension. However, the same timeframe did not reveal a clear reduction in the hazards of minor or major cardiovascular events.

Intriguingly, the initial two years post-implantation actually saw an association with higher hazards of hypertension and both minor and major cardiovascular events. This suggests an initial adaptation phase or potentially reflects the underlying health status of patients who opt for HGNS. Overall, the pattern of findings points towards variable, but potentially beneficial, cardiovascular effects of HGNS that may become more pronounced over longer follow-up periods. The researchers underscore the necessity for further investigation to definitively confirm these associations.

Background: The Burden of Obstructive Sleep Apnea and the Rise of HGNS

Obstructive Sleep Apnea (OSA) represents a significant public health challenge in the United States, affecting millions of individuals. Its insidious nature often leads to chronic cardiovascular strain. The repeated episodes of airway collapse during sleep trigger intermittent hypoxia and sympathetic nervous system activation, creating a fertile ground for cardiovascular pathology. Untreated OSA is a well-established risk factor for a cascade of adverse health outcomes, significantly impacting quality of life and longevity.

The established first-line therapy for OSA is positive airway pressure (PAP) therapy, commonly delivered via a continuous positive airway pressure (CPAP) machine. While effective in managing the airway obstruction, PAP therapy is notorious for its challenges with long-term patient adherence. Many individuals find the mask uncomfortable, the noise disruptive, or the overall experience inconvenient, leading to inconsistent use and diminished therapeutic benefits.

This therapeutic gap paved the way for the development and FDA approval of hypoglossal nerve stimulation (HGNS) as a second-line treatment option for moderate to severe OSA. HGNS involves surgically implanting a device that delivers mild electrical stimulation to the hypoglossal nerve, which controls the tongue. By stimulating this nerve, the device gently moves the tongue forward during sleep, preventing airway collapse. Clinical trials have demonstrated that HGNS leads to higher adherence rates compared to PAP therapy and has shown improvements in objective measures of sleep apnea severity, such as the apnea-hypopnea index (AHI), as well as in patient-reported outcomes like sleepiness and quality of life. However, the long-term cardiovascular implications of this alternative treatment modality have remained a subject of ongoing inquiry.

Study Design and Methodology: A Retrospective Lens on Real-World Data

To address the lingering questions about HGNS and cardiovascular health, this retrospective cohort study meticulously examined data from the Merative MarketScan Commercial Database, a robust source of administrative claims information spanning from 2015 to 2024. The researchers employed a sophisticated propensity score matching technique to ensure that the groups being compared were as similar as possible, thereby minimizing potential confounding factors.

The study identified adults who had undergone HGNS implantation. These patients were then matched with a control group of individuals diagnosed with OSA who met the eligibility criteria for HGNS—meaning they had a confirmed OSA diagnosis via a sleep study and demonstrated nonadherence to PAP therapy—but had not received the implant. The matching process took into account a comprehensive array of baseline covariates, including demographic information, pre-existing medical conditions, and cardiovascular history. Furthermore, the duration of time since their OSA diagnosis and the index year (the year of HGNS implantation or the equivalent index year for controls) were also considered.

A crucial aspect of the study’s design was the modeling of HGNS as a time-varying covariate. This approach allowed the researchers to differentiate between the effects of HGNS within the initial two years following implantation and its potential impact beyond that two-year mark. This temporal distinction is vital for understanding whether any observed cardiovascular benefits or risks are immediate or manifest over a more extended period.

Setting and Analysis: Insights from the U.S. Commercial Insurance Landscape

The data for this comprehensive analysis was drawn from the U.S. commercial insurance claims population, reflecting real-world treatment patterns and outcomes. The analytical work was conducted at the University of Chicago, leveraging the extensive datasets provided by Merative MarketScan. This setting provides a broad overview of healthcare utilization and diagnoses among a significant segment of the insured population in the United States.

Synopsis of Findings: Unveiling the Temporal Trends

The HGNS patient group comprised 3,786 adults, with a notable majority being male (67.7%). The median age within this group was 53.0 years. Following the rigorous propensity score matching, 3,395 HGNS patients were compared against an equal number of matched controls, achieving a high degree of balance across key demographics, comorbidities, and prior cardiovascular history. This meticulous matching is fundamental to attributing observed differences to the HGNS intervention itself.

Early Stage Observations (Within Two Years):

The study unveiled a complex picture regarding the development of new cardiovascular conditions within the first two years of HGNS implantation, particularly among patients who did not have pre-existing cardiovascular disease.

  • Diabetes: For this subgroup, HGNS was not associated with a significantly lower hazard of developing a diabetes diagnosis within two years (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.61 to 1.85). This suggests no immediate protective effect against new-onset diabetes in this initial period.
  • Hypertension: Conversely, HGNS was associated with a higher hazard of a new hypertension diagnosis within the first two years (HR, 1.70; 95% CI, 1.26 to 2.28). This finding is counterintuitive to the potential benefits often attributed to improved sleep quality and may warrant further exploration into the physiological mechanisms at play during the early post-implantation phase.

When examining patients who already had a baseline diagnosis of diabetes or hypertension, the picture for cardiovascular events within the initial two years was also concerning:

  • Minor Cardiovascular Events: HGNS was linked to a higher hazard of diagnoses for minor cardiovascular events, defined as cardiac arrhythmia or coronary artery disease (HR, 1.44; 95% CI, 1.06 to 1.95).
  • Major Cardiovascular Events: Similarly, HGNS was associated with a higher hazard of major cardiovascular event diagnoses, including cerebrovascular disease, heart failure, or myocardial infarction (HR, 1.62; 95% CI, 1.06 to 2.48).

These early-stage findings suggest that the initial period following HGNS implantation may be associated with an increased risk of certain cardiovascular complications, or it may reflect the fact that sicker patients are more likely to opt for this treatment.

Longer-Term Trends (Beyond Two Years):

The study’s temporal modeling revealed a shift in the associations after the two-year mark, hinting at potential long-term advantages.

  • Diabetes: In the subgroup without baseline CVD, HGNS was associated with a significantly lower hazard of diabetes diagnosis after two years (HR, 0.19; 95% CI, 0.09 to 0.38). This represents a substantial reduction in risk and is a key positive finding.
  • Hypertension: For hypertension in the same subgroup, the hazard also decreased significantly after two years (HR, 0.49; 95% CI, 0.33 to 0.73), indicating a potential long-term benefit in managing blood pressure.

Regarding minor and major cardiovascular events after two years:

  • Minor Cardiovascular Events: HGNS was not significantly associated with a lower hazard of minor cardiovascular events (HR, 0.60; 95% CI, 0.35 to 1.04). While not statistically significant at the conventional threshold, the hazard ratio is below 1, suggesting a trend towards benefit.
  • Major Cardiovascular Events: Similarly, HGNS was not significantly associated with a lower hazard of major cardiovascular events (HR, 0.65; 95% CI, 0.31 to 1.36). Again, the hazard ratio is below 1, indicating a possible trend.

However, when the researchers employed time-varying models to analyze the continuous effect of HGNS, the hazards for both minor and major cardiovascular events showed a clear decreasing trend after two years. Specifically, the hazard ratio for minor events dropped to 0.42 (95% CI, 0.22 to 0.79), and for major events, it fell to 0.40 (95% CI, 0.17 to 0.93). These statistically significant findings strongly suggest that HGNS may indeed confer protective cardiovascular benefits over extended periods, even if these benefits are not immediately apparent within the first two years.

Study Limitations: Acknowledging the Nuances

The authors of the study are transparent about its limitations, which are common in large retrospective claims-based analyses. Key among these are:

  • Missing OSA Severity Data: The database does not capture the precise severity of OSA (e.g., AHI scores) for all patients, which could influence the interpretation of outcomes.
  • Absence of Cardiovascular Markers: Detailed physiological markers of cardiovascular health (e.g., blood pressure readings, lipid profiles, ejection fractions) are not available in claims data.
  • Race/Ethnicity Information: The study lacked comprehensive data on race and ethnicity, demographic factors that can influence both OSA and CVD risk and treatment response.
  • Potential Confounding and Surveillance Bias: Despite rigorous matching, residual confounding from unmeasured variables is always a possibility. Additionally, surveillance bias, where patients receiving a new treatment may be more closely monitored, could influence diagnostic rates.

Broader Impact and Implications: A Call for Further Research

The findings of this study offer a glimmer of hope for patients with OSA who struggle with traditional therapies. The potential for HGNS to reduce the incidence of diabetes and hypertension over the long term, coupled with the suggestive trends for reduced cardiovascular events, is a significant development. However, the initial increase in hazards within the first two years necessitates careful consideration and potentially more intensive monitoring of patients during this period.

These results underscore the critical need for prospective, randomized controlled trials with longer follow-up durations. Such studies would be instrumental in confirming these observed associations, elucidating the underlying biological mechanisms driving the observed trends, and establishing definitive guidelines for the use of HGNS in cardiovascular risk management. Clinicians and patients alike must weigh the current evidence, acknowledging both the potential long-term benefits and the initial risks, as treatment decisions are made. The journey to fully understanding the cardiovascular impact of hypoglossal nerve stimulation is ongoing, and this study marks an important step in that direction.

Citation:

Kondamuri N, et al. Hypoglossal nerve stimulation and the incidence of cardiovascular disease. JAMA Otolaryngol Head Neck Surg. 2026;152:858-867. doi:10.1001/jamaoto.2026.1777.